Step 1: create a pool for Thalomid (6%) and a pool for Revlimid (94%) based on percent of damages estimates by Dr. Leitzinger
Step 2: separate each pool into separate pots for consumers and TPPs based on percent of damages, averaging allocation from Leitzinger report of overcharge and unjust enrichment (Exhibit 3 and n.15 to Jeff’s report filed Dec. 14, 2018 (with our supplemental class cert brief))
Step 3: pro rata allocation among consumers / pro rata allocation among TPPs
Described in the notice/court papers:
The Plan of Allocation is as follows: the Net Settlement Fund will be divided into four pools of funds based on Dr. Leitzinger’s calculations as to the allocation of damages [in his December 18, 2018 report]. Based on these calculations, 6% of the Net Settlement Fund will go to Thalomid purchasers (with 10% allocated to consumers and 90% allocated to third party payors). The remaining 94% of the Net Settlement Fund will go to Revlimid purchasers, of which 7.5% will be allocated to consumers, and 92.5% will be allocated to third party payors. Eligible Claimants shall be paid out of each Allocation Pool for which they are eligible. For consumers, the allocation will be determined based on the amount each consumer claimant spent on the drug as a percentage of the total amount spent by all consumer claimants. For third party payors, the allocation will be determined based on the amount each TPP claimant spent as a percentage of the total amount spent by all TPP claimants.